The high prevalence of breast cancer, and the good prognosis for patients with early-stage disease, has motivated an active search for diagnostic biomarkers for breast cancer detection.
Translational relevance
The high prevalence of breast cancer, and the good prognosis for patients with early-stage disease, has motivated an active search for diagnostic biomarkers for breast cancer detection.
Traditional diagnosis by mammography has its limitations as a screening tool, and efforts to identify serum markers have generally revealed a lack of diagnostic ability of serum proteins.
Although there is increasing evidence that microRNAs are linked to malignancy, little is known about the status of circulating microRNAs in breast cancer, or their relationship to microRNAs in the tumour cell. In this study, discriminatory circulating microRNA signatures for breast cancer were identified and validated. Of note, little correlation between tumour and serum expression of microRNAs was observed. The novel microRNA expression signatures identified in this study had sufficient diagnostic efficacy for development into blood-based biomarkers for breast cancer detection.
Introduction
Breast cancer remains the leading cause of mortality in women (1) , despite improvements in cancer screening and treatment strategies. Mammography is the current gold standard for breast cancer detection, but can have false negative rates of up to 20% (NCI data; website http://www.cancer.gov). The diagnosis of breast cancer relies on the histological examination of tissue biopsies, or cytology of fine-needle aspirates, which are both invasive procedures. Known serum-based tumour markers, such as CA15.3 or BR27.29, cannot be used for breast cancer detection due to their low sensitivity (2) . There is thus a need to develop novel markers that are minimally invasive, for the improved detection of breast cancer.
MicroRNAs are approximately 22 nt long non-coding RNAs that can base pair specifically with target mRNAs to induce gene silencing through specific mechanisms involving translational repression or transcript degradation (3) . Since their discovery in 1993 (4), microRNAs have been estimated to regulate more than 60% of all human genes (5), with many microRNAs identified as key players in critical cellular functions such as proliferation (6) and apoptosis (7) . The current database of microRNAs, MirBase release 19, has >2000 entries of human microRNAs, constituting a major class of regulatory molecules.
Iorio et al. provided the earliest observation that microRNAs are differentially expressed in breast cancer tumors as compared to normal breast tissue (8) . Analysis of 76 breast cancer tumours and 10 normal samples (non-cancerous breast tissues) using microarrays which probed for 386 microRNAs, identified 29 dysregulated microRNAs. To identify dysregulated microRNAs, Persson and co-workers (9) performed extensive nextgeneration microRNA sequencing of paired tumour and normal tissue from 5 breast cancer patients, and detected more than 500 microRNAs, including a novel microRNA (miR-4728)
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Author Manuscript Published OnlineFirst on June 24, 2013; DOI: 10.1158/1078-0432.CCR- encoded within the Her2 gene, which was overexpressed in Her2 amplified tumours. A plethora of studies have led to the identification of microRNAs that were differentially expressed depending on breast cancer subtype (10) , histological grade (10), cancer aggressiveness (11, 12) , metastasis-free survival (13, 14) , as well as estrogen receptor (ER) (10, 12, 15, 16) , Her2 (15, 16) , or triple-negative status (11, 12, 14, 15) .
Circulating microRNAs have been suggested to be able to distinguish breast cancer samples from healthy controls. These studies have usually involved targeted analyses of only 4 to 6 microRNAs by RT-PCR (17) (18) (19) . However, comparisons between these studies may not be straightforward as they were carried out under diverse experimental conditions. For example, circulatory microRNAs may have been extracted from serum (17, 18) , plasma (20, 21), circulating tumour cells (22), or even whole blood (19, 23, 24) . Further, while most studies employed serum samples collected pre-operatively as it has been suggested that microRNA levels may return to baseline within 2 weeks after tumour resection, one other study utilized post-operative sera (17, 25) . Circulating microRNAs may also exhibit racial differences, as the microarray profiling of microRNAs in the plasma of 10 cases each from Caucasian and African breast cancer patients resulted in only 2 common dysregulated microRNAs between these groups (20). In contrast to targeted studies involving specific microRNAs, there are few comprehensive profiling studies of circulatory microRNAs in breast cancer (20, 26), and a consistent diagnostic signature for circulatory microRNAs is not yet available.
Few studies have attempted to compare the circulatory microRNA profile to that within the breast cancer tumour, such that the relationship between these two profiles of microRNAs is not clear. One study assessed a panel of seven microRNAs (27) while another analyzed five microRNAs (28). In a third study, four most discriminating microRNAs, selected from discovery profiling of breast cancer tumours (n=84) and normal tissue samples (n=8), were validated using serum samples from breast cancer patients (n=75) and healthy volunteers (n=20) (29). Of these four microRNAs, which were repressed in breast cancer tumours as compared to normal breast tissues, three were also repressed in the sera of breast cancer patients. A recent study (30) investigated the status of four plasma-derived microRNAs in matched tumours, and concluded that microRNAs generally displayed opposite expression patterns in tissue and plasma. However, these comparisons between circulating and tumour microRNA profiles were not comprehensive, as microRNA profiling of the serum or plasma samples were not done. This study aimed to (i) identify significant microRNAs that are differentially expressed in matched breast cancer tumour tissues and sera samples; (ii) investigate the correlation between microRNAs in the tumour with circulating microRNAs; and (iii) validate the serum-derived microRNA signatures in an independent set of serum samples from breast cancer patients (n=132) and healthy controls (n=101).
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Materials and methods

Patients
Patients and healthy volunteers were Singaporeans of Chinese ancestry. Written informed consent was obtained from all contributing patients and volunteers, and ethics approval for this study was obtained from the Centralized Institutional Review Board of SingHealth. Histopathological records (ER, Her2, and lymph node status) were obtained from SingHealth Tissue Repository.
Tissue and serum samples for the profiling stage
Matched fresh frozen breast cancer tumours, adjacent normal tissues, and preoperative sera from 32 breast cancer patients were obtained from the SingHealth Tissue Repository. Control serum samples were recruited from 22 healthy female volunteers. The mean age ± standard deviation for the patients at diagnosis, and healthy volunteers at time of recruitment, were 50 ± 13 years and 47 ± 6 years, respectively. Of the 32 breast cancer patients employed for the profiling stage, 3 (9%), 15 (46%), 9 (28%), or 2 (6%), were diagnosed with stage 1, 2, 3, or 4 cancer, respectively.
All tissue samples were histologically confirmed by a pathologist using hematoxylin and eosin staining of cryosectioned specimens. One tumour sample was rejected due to failure to detect any tumour cells. Except for two samples (with 30% and 40% tumour cells), all tumour tissues employed had a minimum of 60% tumour cells, as estimated microscopically (Supplementary Table S1 ). Overall, the breast cancer tumour samples had an average of about 70% tumour cells. The criteria for adjacent normal tissue were absence of tumour cells and presence of epithelial cells. Hence, after histological confirmation, 31 breast cancer tumours and 23 matched normal tissues were employed for microRNA extraction and profiling using microarray.
Research. RT-PCR (Exiqon, Vedbaek, Denmark), and LNA primers for serum markers (miR-16 and miR-20a).
Reverse transcription and RT-PCR
For QC and individual LNA RT-PCR assays, reverse transcription was carried out using the Universal cDNA Synthesis kit (Exiqon), employing 4ul of microRNA-containing total RNA, 2ul of enzyme mix, and 4ul of 5x reaction buffer, made up to a 20ul reaction volume using nuclease-free water. Reverse transcription was carried out at 42 o C for 60 min, 2160ul of nuclease-free water). Two ml of the diluted cDNA was combined with an equal volume of 2x SYBR Green Master Mix (Exiqon) and dispensed at 10ul per well. The RT-PCR was executed according to Exiqon's protocol for serum and plasma on an Applied Biosystems 7900HT Real-Time PCR System (Life Technologies) which was set using run templates (SDS files) downloaded from Exiqon's website.
The GEO accession number for the microRNA expression profiles from the microarray and RT-PCR panels reported in this study is GSE42128.
Biocomputational analysis
Microarray expression data was imported into the GeneSpring software (Agilent).
Global normalization was carried out based on 90 percentile shift followed by log2 transformation. Principal component analysis (PCA), paired and unpaired t-test, and cluster analysis were computed using the GeneSpring software.
Ct values from RT-PCR were imported into the GenEx software (Exiqon). The analysis workflow included (i) QC using no reverse transcription controls, (ii) interplate calibration, (iii) selection of reference genes using NormFinder and GeNorm, and (iv) normalization and log2 transformation. PCA, cluster analysis, t-test (unpaired, 2-tailed), Mann-Whitney test (2-sided), and Kolmogorov-Smirnov test (for normal distribution) were done using the GenEx software where appropriate.
To derive the most important serum microRNA species for the validation stage, breast cancer associated serum microRNAs that remained significant after Bonferroni correction (n=21), were employed for analysis by collinearity statistics so as to obtain sets of non- of ≥5 was taken as indicative of collinearity, and thus only microRNAs with VIF <5 were employed for logistic regression. Sets of microRNAs were derived with VIF<5 were subjected to binary logistic regression (32, 33). Binary logistic regression was carried out using the PASW software (IBM Corporation, Armonk, NY; version 18) using the Forward: LR (likelihood ratio) method. Receiver operating characteristic (ROC) curves were plotted using PASW.
Data reproducibility
To verify the reproducibility of the microarray platform, technical replicates were 
Results
MicroRNA profiling of tumor and adjacent normal tissue samples
Significant differentially expressed microRNAs were identified by applying the paired t-test (23 pairs of breast cancer tumours vs. adjacent normal tissues) or the unpaired ttest (31 breast cancer tumours vs. 23 adjacent normal tissues). This resulted in 73 microRNAs that were significant (p≤0.05) after correction for multiple testing by Benjamini-Hochberg FDR (false discovery rate) in both paired as well as unpaired t-tests. The 20 most significant microRNAs, with corrected P values ranging from 1.6E-06 to 8.0E-09, are shown in Table 1 .
A complete list of significant microRNAs is provided in Supplementary Table S2 . Seven out of 20 dysregulated microRNAs were overexpressed.
Three component PCA ( Supplementary Fig. S1a ) was able to cluster 84.4% of the samples into tumour and normal tissue groups. Non-supervised hierarchical clustering of the expression profiles of breast cancer tumours and adjacent normal tissues based on Euclidean distance using the 20 most significant microRNAs in a self organizing map was able to cluster the majority of breast cancer tumours from the adjacent normal tissues (Fig. 1a) . Table 2 lists the microRNAs that were significantly associated with ER, Her2, and lymph node positivity, as determined using the unpaired Student's t-test, without correction for FDR. Interestingly, almost all of the differentially expressed microRNAs were novel, with the majority being unique from those identified in other studies (11-13, 15, 16 
MicroRNA profiling of serum samples
Among the 6 suggested reference gene candidates provided in the LNA RT-PCR panels, both the geNorm and NormFinder algorithms identified miR-103 and miR-191 as the most stably expressed, best gene combination for use as reference genes for normalizing the RT-PCR data. Statistical analysis of the serum microRNA profiles led to the identification of 85 microRNAs that were significant (p≤0.05) after FDR correction for multiple testing. The most significant 20 microRNAs are shown in Table 1 , and 18 of these were upregulated in breast cancer. Most of these microRNAs appeared to be novel and have not been reported in the context of circulating microRNA in breast cancer. A complete list of significant microRNAs identified from serum is provided in Supplementary Table S2. PCA ( Supplementary Fig. S1b ) and cluster analysis using the 20 most significant microRNAs (Fig. 1b) , were able to cluster the breast cancer sera from those belonging to healthy controls.
Further, serum microRNAs differentially expressed according to ER, Her2 and lymph node status could also be identified (Table 2) , using the unpaired t-test without correction for FDR. A complete list of serum microRNAs differentially expressed according to ER, Her2 and lymph node status is shown in Supplementary Table S4 .
Inter-platform comparison
Since the serum and tissue samples were extracted and profiled using different kits and platforms, we sought to ascertain that the breast cancer serum and tumour datasets are comparable. Hence, the correlation between the miRVana and miRNeasy extraction methods, and that between the Agilent microRNA microarray and LNA RT-PCR panels, were examined. All the 742 microRNA detected by LNA RT-PCR panels were also included in the microRNA microarray (n=1300). Profiling of the same breast cancer tumour, extracted by 
mirVana or miRNeasy, on the LNA RT-PCR panels showed a high degree of correlation between these extraction methods (R 2 =0.96; Supplementary Fig. S2a ). Profiling of the same breast cancer tumour sample on microarray and RT-PCR showed appreciable correlation for the 742 microRNAs common between these platforms (R 2 =0.61; Supplementary Fig. S2b ), suggesting that they have comparable dynamic ranges, and that the microarray and RT-PCR datasets are comparable.
Comparison between the breast cancer serum and breast cancer tumour profiles
Interestingly, there were only seven common significant microRNAs that were overexpressed in both breast cancer tumours and sera from breast cancer patients, and one microRNA that was down-regulated in both sample types (Table 3 ). Another 13 microRNAs were dysregulated in breast cancer sera and tumours, but in opposite directions. Hence, circulating microRNAs are not highly similar to those within breast cancer cells, suggesting that some microRNAs are released into the circulation selectively.
Validation of miR-1, miR-92a, miR-133a and miR-133b
Twenty-three breast cancer associated serum microRNAs, with P-values that remained significant after Bonferroni correction (P≤1.3E-04), were selected for analysis by collinearity statistics. As a result, three sets of microRNAs were derived, in which each set comprised of ten microRNAs with VIF<5 and were hence not impeded by collinearity (Fig.   2 ). Logistic regression was carried out to identify microRNA signatures with the highest diagnostic efficacy for further validation. As a result, three models were identified (Fig. 2) , which comprise miR-1, miR-92a, miR-133a, and miR-133b as the most important diagnostic microRNA markers.
The four significant microRNAs identified were then subjected to validation by LNA RT-PCR using additional breast cancer sera (n=132) and healthy control sera (n=101). MiR-103 and miR-191, identified earlier by GenEx software as the best reference genes, were employed for data normalization. Validation results were consistent with data from the sera profiling experiments. As expected, all the four microRNAs were overexpressed in breast cancer sera (Fig. 3a) . The log2-fold changes for miR-1, miR-92a, miR-133a, and miR-133b were 2.67, 1.32, 2.52, and 2.41 respectively, comparable to those from the sera profiling experiments (3.59, 1.34, 3.29 and 3.41 respectively). The P-values were highly significant (p<1E-8) for all the four microRNAs (the Mann-Whitney test was used for calculating statistical significance as the Ct values did not follow normal distribution). The resultant ROC curves plotted using the microRNA combinations derived by logistic regression showed areas under the curves (AUCs) of 0.90 to 0.91 (Fig. 3b) , confirming the diagnostic efficacies of the microRNA models. 
Discussion
Among the twenty most significant microRNAs that are differentially expressed in breast cancer tumours identified in this study, several have also been reported to be similarly dysregulated in other studies (Table 1) , attesting to the ability of our approach to isolate known differentially expressed microRNAs associated with breast cancer. Among known tumour-derived microRNAs, mir-145 and miR-21 are amongst the most consistently detected (8, 9) and are hence very attractive candidates for clinical application. Furthermore, the observation from this study that among the 20 most significant differentially expressed microRNAs in breast cancer tumours, 13 were downregulated while only 7 were upregulated, is consistent with the notion that tumorigenesis is apparently more associated with downregulation of tumour-derived microRNAs (8, 34) .
Six out of the 20 most significant tumour-derived microRNAs have not been previously reported in literature in association with breast cancer, suggesting that novel microRNAs can still be identified. The in vitro functionality of these novel microRNAs should be investigated. For example, microRNAs that were upregulated (miR-720, miR1274b and miR-1260), or downregulated (miR-30c, miR-376c and miR-4324), in breast cancer tumours will be likely candidates for novel oncomirs or tumor suppressors, respectively.
Published studies on circulating microRNAs have identified a wide diversity of microRNAs between studies. This is not surprising, considering the wide variation of sample types (plasma, serum, or whole blood) (18, 24, 30) Since the histopathological records for the samples employed in this study were available, we were also able to identify microRNA signatures that were associated with ER, In this study, we employed ROC curve analysis to demonstrate the diagnostic utility of three diagnostic models which were derived from two-marker combinations of miR-1, miR-92a, miR-133a and miR-133b. In a study by Cuk et al, the diagnostic efficacy of four microRNAs (miR-148b, miR-376c, miR-409-3p and miR-801), and that of a three-marker combination (miR-148b, miR-409-3p and miR-801) were evaluated (30). Individually, the Intracellularly, miR-1, miR-92a, miR-133a and miR-133b appear to play tumour suppressor roles in cancer cells (41) (42) (43) (44) . It is not known whether these microRNAs have antitumorigenic properties in their circulating forms. The presence of circulating microRNAs has only been recognized over the last few years (45) , and the understanding of their biological roles is just emerging. Circulating microRNAs have been proposed to play either oncogenic or tumour suppressive roles (37). For example, exosomes containing microRNAs derived from human melanomas and colorectal carcinomas were able to promote tumour growth and immune escape (46) . Alternatively, immunocytes may secrete tumour suppressive microRNAs so as to block tumor proliferation or promote apoptosis (37).
In conclusion, serum-based microRNA signatures associated with breast cancer were successfully derived and validated. The clinical deployment of these signatures as a non- 
invasive diagnostic strategy is promising, and could be validated further for clinically important subtypes of breast cancer such as triple-negative or metastatic breast cancers.
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